Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
BJUI Compass · 2024-12 · 5 (12) · 1299-1306
DOI: 10.1002/bco2.445 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 30.10.2024. Verfasst von Ruth Pidsley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research Sydney New South Wales Australia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council NSW.
Abstract (Originalsprache)
Objectives
We aim to determine the prognostic significance of glutathione S‐transferase Pi 1 DNA methylation ( mGSTP1 ) in two independent prostate cancer cohorts with long‐term clinical follow‐up data. Subjects/Patients and Methods We first re‐examined a published, in‐house whole genome bisulphite sequencing (WGBS) prostate cancer dataset, derived from radical prostatectomy (RP) tissue ( n = 15) with median follow‐up 19.5 years, to confirm and visualise the association between mGSTP1 and patient mortality. To validate prognostic significance, we used a quantitative methylation‐specific head‐loop (MS‐HL) assay to measure mGSTP1 levels in a larger, independent cohort ( n = 186), and performed univariable and multivariable Cox survival analysis.
Results
Re‐analysis of WGBS data showed a significant increase in mGSTP1 in RP samples from patients with lethal versus non‐lethal disease. Subsequent analysis in the larger cohort using the MS‐HL assay confirmed that mGSTP1 was detectable in 97% of RP samples, validating the diagnostic potential of mGSTP1 . Univariable Cox survival analysis revealed a significant association between mGSTP1 levels and biochemical recurrence and metastatic relapse free survival, with a near‐significant association with prostate cancer specific mortality. Notably, multivariable Cox models demonstrated that mGSTP1 did not add independent prognostic value beyond standard clinicopathological features.
Conclusion
Our study supports the importance of DNA methylation as a tissue‐based prostate tumour biomarker. GSTP1 methylation is well established as a diagnostic marker, and in this study, we find that GSTP1 methylation levels are also associated with disease prognosis. Further research is required into the clinical utility of prognostic methylation markers and their functional role in disease progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Garvan Institute of Medical Research Sydney New South Wales Australia.
- School of Clinical Medicine Faculty of Medicine and Health, UNSW Sydney New South Wales Australia.
- Present address: School of Molecular Sciences The University of Western Australia Crawley Western Australia Australia.
- Present address: Harry Perkins Institute of Medical Research Nedlands Western Australia Australia.
- Department of Urology St. Vincent's Sydney New South Wales Australia.
- St Vincent's Prostate Cancer Research Centre Sydney New South Wales Australia.
ORCID-Profile: Ruth Pidsley, Phillip Stricker, Susan J Clark
Förderung
- Cancer Council NSW
Zitieren
APA
Pidsley, R., Lam, D., Qu, W., Stricker, P., Kench, J. G., Horvath, L. G., & Clark, S. J. (2024). Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. BJUI Compass, 5(12), 1299-1306. https://doi.org/10.1002/bco2.445
Vancouver
Pidsley R, Lam D, Qu W, Stricker P, Kench JG, Horvath LG, et al. Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. BJUI Compass. 2024;5(12):1299-1306. doi:10.1002/bco2.445
BibTeX
@article{Pidsley2024,
author = {Pidsley, Ruth and Lam, Dilys and Qu, Wenjia and Stricker, Phillip and Kench, James G and Horvath, Lisa G and Clark, Susan J},
title = {Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer},
journal = {BJUI Compass},
year = {2024},
volume = {5},
number = {12},
pages = {1299--1306},
doi = {10.1002/bco2.445}
}
EUVIMED